Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Difficulties defining the role of high-dose chemotherapy in the management of breast cancer.

× No keyword cloud information.

8 in total

1. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

Authors: W P Sheridan; C G Begley; C A Juttner; J Szer; L B To; D Maher; K M McGrath; G Morstyn; R M Fox
Journal: Lancet Date: 1992-03-14 Impact factor: 79.321

2. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.

Authors: W P Peters; E J Shpall; R B Jones; G A Olsen; R C Bast; J P Gockerman; J O Moore
Journal: J Clin Oncol Date: 1988-09 Impact factor: 44.544

3. More is better.

Authors: W M Hryniuk
Journal: J Clin Oncol Date: 1988-09 Impact factor: 44.544

Review 4. The importance of dose intensity in chemotherapy of metastatic breast cancer.

Authors: W Hryniuk; H Bush
Journal: J Clin Oncol Date: 1984-11 Impact factor: 44.544

5. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.

Authors: K Swenerton; J Jeffrey; G Stuart; M Roy; G Krepart; J Carmichael; P Drouin; R Stanimir; G O'Connell; G MacLean
Journal: J Clin Oncol Date: 1992-05 Impact factor: 44.544

6. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.

Authors: D S Alberts; S Green; E V Hannigan; R O'Toole; D Stock-Novack; P Anderson; E A Surwit; V K Malvlya; W A Nahhas; C J Jolles
Journal: J Clin Oncol Date: 1992-05 Impact factor: 44.544

Review 7. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.

Authors:
Journal: J Clin Oncol Date: 1994-11 Impact factor: 44.544

8. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.

Authors: W P Peters; M Ross; J J Vredenburgh; B Meisenberg; L B Marks; E Winer; J Kurtzberg; R C Bast; R Jones; E Shpall
Journal: J Clin Oncol Date: 1993-06 Impact factor: 44.544

8 in total